Dr. William R. Gwin III, MD
Medical Oncology (Medical Oncology Physician)
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 98
Licensed in Washington since 2009, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD60094874 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 322
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 136 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 72 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Hospital discharge day management, 30 minutes or less | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Seattle, WA | 43 |
| Anastrozole Other prescribers in Seattle, WA | 19 |
| Tamoxifen Citrate Other prescribers in Seattle, WA | 18 |
| Kisqali (ribociclib succinate) | 15 |
| Ibrance (palbociclib) | 14 |
| Truqap (capivasertib) | 12 |
| Ondansetron Hcl Other prescribers in Seattle, WA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 11 payments worth $7,819 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $7,093 |
|---|---|
| Gilead Sciences, Inc. | $580 |
| Stemline Therapeutics Inc. | $146 |
| Consulting Fee | $7,415 |
|---|---|
| Food and Beverage | $360 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Consulting Fee Truqap · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Consulting Fee | $2,050 |
| AstraZeneca Pharmaceuticals LP Jul 24, 2025 | Consulting Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $685 |
| Gilead Sciences, Inc. Feb 6, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4146651;VEM US;10048869 | $580 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $285,738 in research payments for these studies, mostly to the institutions running them.
- A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Daiichi Sankyo Inc. · Completed · NCT04699630 - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Eli Lilly and Company · Completed · NCT02675231 - Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of pati…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.